Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia
Background The overall survival (OS) rate of adult patients suffering from acute myeloid leukaemia (AML) remains unsatisfactory at less than 40%. Current risk stratification systems fail to provide accurate guidelines for precise treatment. Novel biomarkers for predicting prognosis are urgently need...
Gespeichert in:
| Veröffentlicht in: | Molecular biology reports 2023-10, Vol.50 (10), p.8445-8457 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8457 |
|---|---|
| container_issue | 10 |
| container_start_page | 8445 |
| container_title | Molecular biology reports |
| container_volume | 50 |
| creator | Guo, Zhibo Guo, Dan Kong, Desheng Bian, Sicheng Zhao, Linlin Li, Qi Lin, Leilei Hao, Jiali Sun, Lili Li, Yinghua |
| description | Background
The overall survival (OS) rate of adult patients suffering from acute myeloid leukaemia (AML) remains unsatisfactory at less than 40%. Current risk stratification systems fail to provide accurate guidelines for precise treatment. Novel biomarkers for predicting prognosis are urgently needed. Plexin B2 (PLXNB2), a functional receptor of angiogenin (ANG), has been found to be aberrantly expressed in multitudinous tumours. We detected overexpression of PLXNB2 mRNA in AML via transcriptome microarray analysis. This study aims to explore the potential role of PLXNB2 as a biomarker of prognosis and a prospective target of AML.
Methods
qRT‒PCR was conducted to verify the expression of PLXNB2 mRNA in bone marrow mononuclear cells from AML patients. Immunohistochemical and immunofluorescence staining were performed and confirmed increased expression of PLXNB2 protein in AML bone marrow tissues. Data on PLXNB2 expression, prognosis and clinical features were accessed from multiple bioinformatic databases, including The Cancer Genome Atlas (TCGA). Genes coexpressed and correlated with PLXNB2 were identified and analysed in the TCGA AML cohort. Metascape was applied for functional and pathway enrichment analysis of genes related to PLXNB2. Small molecular agents and traditional Chinese medicines potentially targeting genes related to PLXNB2 were screened via the Connectivity Map, TCMSP and HIT databases.
Results
PLXNB2 mRNA and protein levels are higher in AML samples than in normal controls. Overexpression of PLXNB2 is associated with worse OS in AML. Patients with high PLXNB2 expression might benefit more from haematopoietic stem cell transplantation (HSCT) (indicated by prolonged OS) than those with only chemotherapy treatment. Differentially expressed genes between the high and low PLXNB2 expression groups were overlapped with PLXNB2-coexpressed genes, and genes that overlapped were enriched in immune functions, endothelial cell regulation and cell interaction gene sets, indicating the potential function of PLXNB2 in AML. A total of 36 hub genes were identified from the differentially expressed genes, and MRC1, IL10, CD163 and CCL22 had significant prognostic value for AML. Analysis of the connectivity map and traditional agents revealed that honokiol, morphines, triptolide and paeoniflorin could be potential treatment regimens.
Conclusions
The overexpression of PLXNB2 is an adverse prognostic factor in adult AML patients and could be used as a potentia |
| doi_str_mv | 10.1007/s11033-023-08721-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857853767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2868486075</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-85060d60a6def85aba6706e3fd30982f05885c8339f3168acc61a38086d8ee783</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS1EpS6FL9BTJC4cCIw9sT17hKr8kVbQQyv1ZhlnXLlknSVOVPbb18siIXGAw2hGer_3DvOEOJfwRgLYt0VKQGxB1SGrZPvwRKyktth2a0tPxQoQZNuRlqfiWSn3ANBJq1ciXv7cTVxKGnPjsx_2JZXXTRhSTsEPTUl3OcV65sBV75vdOHOeU5XiksN8sI2xudrcfnmvmlQzwjJzs93zMKa-GXj57nmb_HNxEv1Q-MXvfSZuPlxeX3xqN18_fr54t2kDoplb0mCgN-BNz5G0_-aNBcMYe4Q1qQiaSAdCXEeUhnwIRnokINMTsyU8E6-Oubtp_LFwmd02lcDD4DOPS3EoNSpQynT_RRVpSxqtsRV9-Rd6Py5T_daBMtSRAasrpY5UmMZSJo5uN6Wtn_ZOgju05I4tudqS-9WSe6gmPJpKhfMdT3-i_-F6BFG8lJ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2868486075</pqid></control><display><type>article</type><title>Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia</title><source>Springer Nature - Complete Springer Journals</source><creator>Guo, Zhibo ; Guo, Dan ; Kong, Desheng ; Bian, Sicheng ; Zhao, Linlin ; Li, Qi ; Lin, Leilei ; Hao, Jiali ; Sun, Lili ; Li, Yinghua</creator><creatorcontrib>Guo, Zhibo ; Guo, Dan ; Kong, Desheng ; Bian, Sicheng ; Zhao, Linlin ; Li, Qi ; Lin, Leilei ; Hao, Jiali ; Sun, Lili ; Li, Yinghua</creatorcontrib><description>Background
The overall survival (OS) rate of adult patients suffering from acute myeloid leukaemia (AML) remains unsatisfactory at less than 40%. Current risk stratification systems fail to provide accurate guidelines for precise treatment. Novel biomarkers for predicting prognosis are urgently needed. Plexin B2 (PLXNB2), a functional receptor of angiogenin (ANG), has been found to be aberrantly expressed in multitudinous tumours. We detected overexpression of PLXNB2 mRNA in AML via transcriptome microarray analysis. This study aims to explore the potential role of PLXNB2 as a biomarker of prognosis and a prospective target of AML.
Methods
qRT‒PCR was conducted to verify the expression of PLXNB2 mRNA in bone marrow mononuclear cells from AML patients. Immunohistochemical and immunofluorescence staining were performed and confirmed increased expression of PLXNB2 protein in AML bone marrow tissues. Data on PLXNB2 expression, prognosis and clinical features were accessed from multiple bioinformatic databases, including The Cancer Genome Atlas (TCGA). Genes coexpressed and correlated with PLXNB2 were identified and analysed in the TCGA AML cohort. Metascape was applied for functional and pathway enrichment analysis of genes related to PLXNB2. Small molecular agents and traditional Chinese medicines potentially targeting genes related to PLXNB2 were screened via the Connectivity Map, TCMSP and HIT databases.
Results
PLXNB2 mRNA and protein levels are higher in AML samples than in normal controls. Overexpression of PLXNB2 is associated with worse OS in AML. Patients with high PLXNB2 expression might benefit more from haematopoietic stem cell transplantation (HSCT) (indicated by prolonged OS) than those with only chemotherapy treatment. Differentially expressed genes between the high and low PLXNB2 expression groups were overlapped with PLXNB2-coexpressed genes, and genes that overlapped were enriched in immune functions, endothelial cell regulation and cell interaction gene sets, indicating the potential function of PLXNB2 in AML. A total of 36 hub genes were identified from the differentially expressed genes, and MRC1, IL10, CD163 and CCL22 had significant prognostic value for AML. Analysis of the connectivity map and traditional agents revealed that honokiol, morphines, triptolide and paeoniflorin could be potential treatment regimens.
Conclusions
The overexpression of PLXNB2 is an adverse prognostic factor in adult AML patients and could be used as a potential biomarker. PLXNB2 might exert an oncogenic role by modulating immune functions, endothelial cell functions and cell interactions. AML patients with high PLXNB2 expression could benefit more from HSCT.
Highlights
PLXNB2 expression could be a potential biomarker of poor prognosis in AML.
HSCT could improve the prognosis of patients with high PLXNB2 expression.
PLXNB2 might regulate immunity, endothelial cells and cell interactions.</description><identifier>ISSN: 0301-4851</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-023-08721-w</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acute myeloid leukemia ; adults ; Angiogenin ; Animal Anatomy ; Animal Biochemistry ; bioinformatics ; Biomarkers ; Biomedical and Life Sciences ; Bone marrow ; CD163 antigen ; Cell interactions ; cell transplantation ; Chemotherapy ; Clinical significance ; DNA microarrays ; drug therapy ; Endothelial cells ; fluorescent antibody technique ; Gene expression ; gene expression regulation ; genes ; Genomes ; Hematopoietic stem cells ; Histology ; honokiol ; Immunofluorescence ; immunohistochemistry ; interleukin-10 ; Leukemia ; Leukocytes (mononuclear) ; Life Sciences ; Medical prognosis ; microarray technology ; Morphology ; myeloid leukemia ; Original Article ; Patients ; Prognosis ; risk assessment ; Stem cell transplantation ; Traditional Chinese medicine ; transcriptome ; Transcriptomes ; Triptolide</subject><ispartof>Molecular biology reports, 2023-10, Vol.50 (10), p.8445-8457</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c336t-85060d60a6def85aba6706e3fd30982f05885c8339f3168acc61a38086d8ee783</cites><orcidid>0000-0002-8060-8221</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11033-023-08721-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11033-023-08721-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Guo, Zhibo</creatorcontrib><creatorcontrib>Guo, Dan</creatorcontrib><creatorcontrib>Kong, Desheng</creatorcontrib><creatorcontrib>Bian, Sicheng</creatorcontrib><creatorcontrib>Zhao, Linlin</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Lin, Leilei</creatorcontrib><creatorcontrib>Hao, Jiali</creatorcontrib><creatorcontrib>Sun, Lili</creatorcontrib><creatorcontrib>Li, Yinghua</creatorcontrib><title>Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><description>Background
The overall survival (OS) rate of adult patients suffering from acute myeloid leukaemia (AML) remains unsatisfactory at less than 40%. Current risk stratification systems fail to provide accurate guidelines for precise treatment. Novel biomarkers for predicting prognosis are urgently needed. Plexin B2 (PLXNB2), a functional receptor of angiogenin (ANG), has been found to be aberrantly expressed in multitudinous tumours. We detected overexpression of PLXNB2 mRNA in AML via transcriptome microarray analysis. This study aims to explore the potential role of PLXNB2 as a biomarker of prognosis and a prospective target of AML.
Methods
qRT‒PCR was conducted to verify the expression of PLXNB2 mRNA in bone marrow mononuclear cells from AML patients. Immunohistochemical and immunofluorescence staining were performed and confirmed increased expression of PLXNB2 protein in AML bone marrow tissues. Data on PLXNB2 expression, prognosis and clinical features were accessed from multiple bioinformatic databases, including The Cancer Genome Atlas (TCGA). Genes coexpressed and correlated with PLXNB2 were identified and analysed in the TCGA AML cohort. Metascape was applied for functional and pathway enrichment analysis of genes related to PLXNB2. Small molecular agents and traditional Chinese medicines potentially targeting genes related to PLXNB2 were screened via the Connectivity Map, TCMSP and HIT databases.
Results
PLXNB2 mRNA and protein levels are higher in AML samples than in normal controls. Overexpression of PLXNB2 is associated with worse OS in AML. Patients with high PLXNB2 expression might benefit more from haematopoietic stem cell transplantation (HSCT) (indicated by prolonged OS) than those with only chemotherapy treatment. Differentially expressed genes between the high and low PLXNB2 expression groups were overlapped with PLXNB2-coexpressed genes, and genes that overlapped were enriched in immune functions, endothelial cell regulation and cell interaction gene sets, indicating the potential function of PLXNB2 in AML. A total of 36 hub genes were identified from the differentially expressed genes, and MRC1, IL10, CD163 and CCL22 had significant prognostic value for AML. Analysis of the connectivity map and traditional agents revealed that honokiol, morphines, triptolide and paeoniflorin could be potential treatment regimens.
Conclusions
The overexpression of PLXNB2 is an adverse prognostic factor in adult AML patients and could be used as a potential biomarker. PLXNB2 might exert an oncogenic role by modulating immune functions, endothelial cell functions and cell interactions. AML patients with high PLXNB2 expression could benefit more from HSCT.
Highlights
PLXNB2 expression could be a potential biomarker of poor prognosis in AML.
HSCT could improve the prognosis of patients with high PLXNB2 expression.
PLXNB2 might regulate immunity, endothelial cells and cell interactions.</description><subject>Acute myeloid leukemia</subject><subject>adults</subject><subject>Angiogenin</subject><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>bioinformatics</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Bone marrow</subject><subject>CD163 antigen</subject><subject>Cell interactions</subject><subject>cell transplantation</subject><subject>Chemotherapy</subject><subject>Clinical significance</subject><subject>DNA microarrays</subject><subject>drug therapy</subject><subject>Endothelial cells</subject><subject>fluorescent antibody technique</subject><subject>Gene expression</subject><subject>gene expression regulation</subject><subject>genes</subject><subject>Genomes</subject><subject>Hematopoietic stem cells</subject><subject>Histology</subject><subject>honokiol</subject><subject>Immunofluorescence</subject><subject>immunohistochemistry</subject><subject>interleukin-10</subject><subject>Leukemia</subject><subject>Leukocytes (mononuclear)</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>microarray technology</subject><subject>Morphology</subject><subject>myeloid leukemia</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>risk assessment</subject><subject>Stem cell transplantation</subject><subject>Traditional Chinese medicine</subject><subject>transcriptome</subject><subject>Transcriptomes</subject><subject>Triptolide</subject><issn>0301-4851</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU9v1DAQxS1EpS6FL9BTJC4cCIw9sT17hKr8kVbQQyv1ZhlnXLlknSVOVPbb18siIXGAw2hGer_3DvOEOJfwRgLYt0VKQGxB1SGrZPvwRKyktth2a0tPxQoQZNuRlqfiWSn3ANBJq1ciXv7cTVxKGnPjsx_2JZXXTRhSTsEPTUl3OcV65sBV75vdOHOeU5XiksN8sI2xudrcfnmvmlQzwjJzs93zMKa-GXj57nmb_HNxEv1Q-MXvfSZuPlxeX3xqN18_fr54t2kDoplb0mCgN-BNz5G0_-aNBcMYe4Q1qQiaSAdCXEeUhnwIRnokINMTsyU8E6-Oubtp_LFwmd02lcDD4DOPS3EoNSpQynT_RRVpSxqtsRV9-Rd6Py5T_daBMtSRAasrpY5UmMZSJo5uN6Wtn_ZOgju05I4tudqS-9WSe6gmPJpKhfMdT3-i_-F6BFG8lJ8</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Guo, Zhibo</creator><creator>Guo, Dan</creator><creator>Kong, Desheng</creator><creator>Bian, Sicheng</creator><creator>Zhao, Linlin</creator><creator>Li, Qi</creator><creator>Lin, Leilei</creator><creator>Hao, Jiali</creator><creator>Sun, Lili</creator><creator>Li, Yinghua</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-8060-8221</orcidid></search><sort><creationdate>20231001</creationdate><title>Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia</title><author>Guo, Zhibo ; Guo, Dan ; Kong, Desheng ; Bian, Sicheng ; Zhao, Linlin ; Li, Qi ; Lin, Leilei ; Hao, Jiali ; Sun, Lili ; Li, Yinghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-85060d60a6def85aba6706e3fd30982f05885c8339f3168acc61a38086d8ee783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute myeloid leukemia</topic><topic>adults</topic><topic>Angiogenin</topic><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>bioinformatics</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Bone marrow</topic><topic>CD163 antigen</topic><topic>Cell interactions</topic><topic>cell transplantation</topic><topic>Chemotherapy</topic><topic>Clinical significance</topic><topic>DNA microarrays</topic><topic>drug therapy</topic><topic>Endothelial cells</topic><topic>fluorescent antibody technique</topic><topic>Gene expression</topic><topic>gene expression regulation</topic><topic>genes</topic><topic>Genomes</topic><topic>Hematopoietic stem cells</topic><topic>Histology</topic><topic>honokiol</topic><topic>Immunofluorescence</topic><topic>immunohistochemistry</topic><topic>interleukin-10</topic><topic>Leukemia</topic><topic>Leukocytes (mononuclear)</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>microarray technology</topic><topic>Morphology</topic><topic>myeloid leukemia</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>risk assessment</topic><topic>Stem cell transplantation</topic><topic>Traditional Chinese medicine</topic><topic>transcriptome</topic><topic>Transcriptomes</topic><topic>Triptolide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Zhibo</creatorcontrib><creatorcontrib>Guo, Dan</creatorcontrib><creatorcontrib>Kong, Desheng</creatorcontrib><creatorcontrib>Bian, Sicheng</creatorcontrib><creatorcontrib>Zhao, Linlin</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Lin, Leilei</creatorcontrib><creatorcontrib>Hao, Jiali</creatorcontrib><creatorcontrib>Sun, Lili</creatorcontrib><creatorcontrib>Li, Yinghua</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Zhibo</au><au>Guo, Dan</au><au>Kong, Desheng</au><au>Bian, Sicheng</au><au>Zhao, Linlin</au><au>Li, Qi</au><au>Lin, Leilei</au><au>Hao, Jiali</au><au>Sun, Lili</au><au>Li, Yinghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><date>2023-10-01</date><risdate>2023</risdate><volume>50</volume><issue>10</issue><spage>8445</spage><epage>8457</epage><pages>8445-8457</pages><issn>0301-4851</issn><eissn>1573-4978</eissn><abstract>Background
The overall survival (OS) rate of adult patients suffering from acute myeloid leukaemia (AML) remains unsatisfactory at less than 40%. Current risk stratification systems fail to provide accurate guidelines for precise treatment. Novel biomarkers for predicting prognosis are urgently needed. Plexin B2 (PLXNB2), a functional receptor of angiogenin (ANG), has been found to be aberrantly expressed in multitudinous tumours. We detected overexpression of PLXNB2 mRNA in AML via transcriptome microarray analysis. This study aims to explore the potential role of PLXNB2 as a biomarker of prognosis and a prospective target of AML.
Methods
qRT‒PCR was conducted to verify the expression of PLXNB2 mRNA in bone marrow mononuclear cells from AML patients. Immunohistochemical and immunofluorescence staining were performed and confirmed increased expression of PLXNB2 protein in AML bone marrow tissues. Data on PLXNB2 expression, prognosis and clinical features were accessed from multiple bioinformatic databases, including The Cancer Genome Atlas (TCGA). Genes coexpressed and correlated with PLXNB2 were identified and analysed in the TCGA AML cohort. Metascape was applied for functional and pathway enrichment analysis of genes related to PLXNB2. Small molecular agents and traditional Chinese medicines potentially targeting genes related to PLXNB2 were screened via the Connectivity Map, TCMSP and HIT databases.
Results
PLXNB2 mRNA and protein levels are higher in AML samples than in normal controls. Overexpression of PLXNB2 is associated with worse OS in AML. Patients with high PLXNB2 expression might benefit more from haematopoietic stem cell transplantation (HSCT) (indicated by prolonged OS) than those with only chemotherapy treatment. Differentially expressed genes between the high and low PLXNB2 expression groups were overlapped with PLXNB2-coexpressed genes, and genes that overlapped were enriched in immune functions, endothelial cell regulation and cell interaction gene sets, indicating the potential function of PLXNB2 in AML. A total of 36 hub genes were identified from the differentially expressed genes, and MRC1, IL10, CD163 and CCL22 had significant prognostic value for AML. Analysis of the connectivity map and traditional agents revealed that honokiol, morphines, triptolide and paeoniflorin could be potential treatment regimens.
Conclusions
The overexpression of PLXNB2 is an adverse prognostic factor in adult AML patients and could be used as a potential biomarker. PLXNB2 might exert an oncogenic role by modulating immune functions, endothelial cell functions and cell interactions. AML patients with high PLXNB2 expression could benefit more from HSCT.
Highlights
PLXNB2 expression could be a potential biomarker of poor prognosis in AML.
HSCT could improve the prognosis of patients with high PLXNB2 expression.
PLXNB2 might regulate immunity, endothelial cells and cell interactions.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><doi>10.1007/s11033-023-08721-w</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-8060-8221</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-4851 |
| ispartof | Molecular biology reports, 2023-10, Vol.50 (10), p.8445-8457 |
| issn | 0301-4851 1573-4978 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2857853767 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Acute myeloid leukemia adults Angiogenin Animal Anatomy Animal Biochemistry bioinformatics Biomarkers Biomedical and Life Sciences Bone marrow CD163 antigen Cell interactions cell transplantation Chemotherapy Clinical significance DNA microarrays drug therapy Endothelial cells fluorescent antibody technique Gene expression gene expression regulation genes Genomes Hematopoietic stem cells Histology honokiol Immunofluorescence immunohistochemistry interleukin-10 Leukemia Leukocytes (mononuclear) Life Sciences Medical prognosis microarray technology Morphology myeloid leukemia Original Article Patients Prognosis risk assessment Stem cell transplantation Traditional Chinese medicine transcriptome Transcriptomes Triptolide |
| title | Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A04%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20analysis,%20clinical%20significance%20and%20potential%20function%20of%20PLXNB2%20in%20acute%20myeloid%20leukaemia&rft.jtitle=Molecular%20biology%20reports&rft.au=Guo,%20Zhibo&rft.date=2023-10-01&rft.volume=50&rft.issue=10&rft.spage=8445&rft.epage=8457&rft.pages=8445-8457&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-023-08721-w&rft_dat=%3Cproquest_cross%3E2868486075%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2868486075&rft_id=info:pmid/&rfr_iscdi=true |